PharmAbcine signs a CMO contract with Binex
so Binex can produce olinvacimab at its new 5,000L production line
Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340ks), a
biotech company focusing on the development of antibody therapeutics,
announced on August 31 that it had signed a contract manufacturing
organization(CMO) agreement with Binex, a leading biologics CDMO(Contract
Development and Manufacturing Organization) company in Korea.
new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine's leading
antibody therapeutics pipeline in oncology, using the new 5,000L production
line while it was previously produced in the 1,000L production line. This
contract will allow Binex to start the operation of its new 5,000L production
line designed for large-scale commercial production.
PharmAbcine, this agreement will accommodate more timely and less costly
delivery of Olinvacimab for its rapidly expanding list of both clinical and
non-clinical studies. The list of studies includes, among others, the global
clinical trial for Avastin refractory rGBM(recurrent glioblastoma multiforme)
patients, the global combination trial with pembrolizumab for mTNBC(metastatic
triple negative breast cancer), the research collaboration with SLBio in China
for non-small cell lung cancer therapeutics, multiple investigator-initiated
studies planned for solid tumors, etc.
are very pleased with this agreement as Binex has been a very reliable clinical
manufacturing partner since the very beginning of the clinical trials," said
Dr. Jin-San Yoo, CEO of PharmAbcine. "This agreement bodes well with our
business strategy of aggressively expanding the indications of our front runner
(053030, KQ) is a biologics contract development and manufacturing organization
located in South Korea. It has provided full range services from cell line
development to GMP manufacturing for both the drug substance and drug product.
CDMO services offered by Binex covers sophisticated analytic services and cGMP
manufacturing for IMPs and commercial products (mAb/recombinant protein),
leading to successful approval for INDs and BLAs of clients' project. Binex'
CDMO capability has already been acknowledged not only by regulatory
authorities in advanced countries but also by top pharmaceutical companies who
want to in-license and commercialize biologics pipeline manufactured by Binex.
For more information, please visit http://www.bi-nex.com.
is a clinical-stage biotech company focusing on the development of fully human
antibody therapeutics to treat neovascular disorders, tumors, and other
medically unmet diseases. It provides therapeutic antibodies for a wide
spectrum of indications from oncology, immuno-oncology, ophthalmology,
respiratory, to renal pathology.
leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is
currently in a phase II study for bevacizumab-nonresponding rGBM
(recurrent glioblastoma multiforme) patients in both US and Australia. In
collaboration with MERCK, olinvacimab plus pembrolizumab Phase Ib trials for
mTNBC and rGBM are on-going.
has its own HuPhage library and innovative selection system. PharmAbcine's
advanced 3G expression system accommodates high levels of antibody
production with high reproducibility. With its highly advanced technology
platforms, it provides high-quality antibody generation services. The high
standards have allowed PharmAbcine to expand co-development opportunities with
not only existing but also potential partners.
information about PharmAbcine can be found on website at http://www.pharmabcine.com.
Sungjun Park, email@example.com, +82-70-4270-2637